Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019	2018 - 2015
Revenue	36.28	52.12	33.05	57.99	43.1	Upgrade
Revenue Growth (YoY)	-30.40%	57.69%	-43.01%	34.55%	41.63%	Upgrade
Gross Profit	36.28	52.12	33.05	57.99	43.1	Upgrade
Selling, General & Admin	116.5	90.31	71.1	44.17	41.06	Upgrade
Research & Development	435.07	419.98	229.81	150.41	108.41	Upgrade
Operating Expenses	551.57	510.29	300.9	194.58	149.47	Upgrade
Operating Income	-515.29	-458.16	-267.85	-136.58	-106.37	Upgrade
Other Expense / Income	-34.1	16.02	0.04	-2.35	-6.84	Upgrade
Pretax Income	-481.19	-474.19	-267.89	-134.23	-99.53	Upgrade
Net Income	-481.19	-474.19	-267.89	-134.23	-99.53	Upgrade
Shares Outstanding (Basic)	89	77	71	56	47	Upgrade
Shares Outstanding (Diluted)	89	77	71	56	47	Upgrade
Shares Change	15.33%	8.57%	26.63%	18.50%	9.70%	Upgrade
EPS (Basic)	-5.42	-6.16	-3.78	-2.40	-2.11	Upgrade
EPS (Diluted)	-5.42	-6.16	-3.78	-2.40	-2.11	Upgrade
Free Cash Flow	-408.07	-346.7	-237.79	-53.5	-110.03	Upgrade
Free Cash Flow Per Share	-4.60	-4.50	-3.35	-0.96	-2.33	Upgrade
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	Upgrade
Operating Margin	-1420.51%	-879.04%	-810.37%	-235.51%	-246.78%	Upgrade
Profit Margin	-1326.51%	-909.78%	-810.49%	-231.46%	-230.92%	Upgrade
Free Cash Flow Margin	-1124.94%	-665.17%	-719.41%	-92.25%	-255.28%	Upgrade
EBITDA	-472.22	-466.61	-261	-127.92	-93.95	Upgrade
EBITDA Margin	-1301.77%	-895.25%	-789.64%	-220.57%	-217.96%	Upgrade
Depreciation & Amortization	8.98	7.57	6.89	6.31	5.59	Upgrade
EBIT	-481.19	-474.19	-267.89	-134.23	-99.53	Upgrade
EBIT Margin	-1326.51%	-909.78%	-810.49%	-231.46%	-230.92%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).